New 52 Week Low Today

Hepion Pharmaceuticals Inc HEPA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/10/24 EDT
1.27quote price arrow down-0.04 (-3.05%)
Volume
85,958
52 week range
1.19 - 20.66
Loading...
  • Open1.29
  • Day High1.38
  • Day Low1.19
  • Prev Close1.31
  • 52 Week High20.66
  • 52 Week High Date05/23/23
  • 52 Week Low1.19
  • 52 Week Low Date05/10/24

Key Stats

  • Market Cap6.95M
  • Shares Out5.47M
  • 10 Day Average Volume0.03M
  • Dividend-
  • Dividend Yield-
  • Beta1.72
  • YTD % Change-61.11

KEY STATS

  • Open1.29
  • Day High1.38
  • Day Low1.19
  • Prev Close1.31
  • 52 Week High20.66
  • 52 Week High Date05/23/23
  • 52 Week Low1.19
  • 52 Week Low Date05/10/24
  • Market Cap6.95M
  • Shares Out5.47M
  • 10 Day Average Volume0.03M
  • Dividend-
  • Dividend Yield-
  • Beta1.72
  • YTD % Change-61.11

RATIOS/PROFITABILITY

  • EPS (TTM)-12.41
  • P/E (TTM)-0.10
  • Fwd P/E (NTM)-0.11
  • EBITDA (TTM)-45.191M
  • ROE (TTM)-182.07%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/13/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Hepion Pharmaceuticals Inc

 

Profile

MORE
Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of drug therapy for treatment of chronic liver diseases. The Company is developing a treatment for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), and other chronic liver diseases. Its cyclophilin inhibitor, rencofilstat, is being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease. It is...
John Brancaccio CPA
Independent Chairman of the Board
John Cavan
Interim Chief Executive Officer
Address
399 Thornall St
Edison, NJ
08837-2236
United States